Cellectar Biosciences, Inc.
Records under this name other than the patents Cellectar Biosciences, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 8 patents it holds.
Showing 1 to 5 of 5 · Back to Cellectar Biosciences, Inc.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,550,002 | Phospholipid analogs as diapeutic agents and methods thereof Term ended Term ended Dec 23, 2025 · From the USPTO record | Term ended | Term ended Dec 23, 2025 | From the USPTO record |
| US 9,579,406 | Phospholipid ether analogs as agents for detecting and locating cancer, and methods thereof Term ended Term ended Dec 17, 2025 · From the USPTO record | Term ended | Term ended Dec 17, 2025 | From the USPTO record |
| US 6,312,734 | Methods for production of the oxidized glutathione composite with cis-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanisms for normal and transformed cells Term ended Term ended Feb 1, 2019 · From the USPTO record | Term ended | Term ended Feb 1, 2019 | From the USPTO record |
| US 7,169,412 | Methods for production of the oxidized glutathione composite with cis-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanisms for normal and transformed cells Term ended Ended no later than Jan 27, 2019 · From the USPTO record | Term ended | Ended no later than Jan 27, 2019 | From the USPTO record |
| US 7,371,411 | Methods for production of the oxidized glutathione composite with CIS-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanisms for normal and transformed cells Lapsed on the fee record Ended May 13, 2016 · From the USPTO record | Lapsed on the fee record | Ended May 13, 2016 | From the USPTO record |